On treatment of schizophrenia with medication, evidence-based guidelines agree on definitive recommendations for only a small number of issues: antipsychotic drugs should be used to reduce symptoms and the risk of relapse and rehospitalization, and clozapine is indicated for treatment-resistant schizophrenia and people with persistent suicidality or hostility.1,2 The guidelines also provide more granular recommendations on how and when to use antipsychotic drugs. The evidence and guidelines are murkier on other issues, such as the use of other types of psychotropic medications, combinations of antipsychotic agents, and the role of long-acting, injectable antipsychotic drugs.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Stroup TS. Clozapine and Evidence-Based Psychopharmacology for Schizophrenia. JAMA Psychiatry. 2019;76(10):1007–1008. doi:10.1001/jamapsychiatry.2019.1656
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: